The Alzheimer's disease treatment landscape is rapidly changing, with several new FDA-approved antibody therapies that target amyloid plaque and aim to slow disease progression. While the controversial approval of aducanumab faced challenges, newer drugs like lecanemab and donanemab have shown more promising results in clinical trials, demonstrating cognitive benefits. Additionally, the pipeline includes novel therapies targeting tau protein and other mechanisms. Advancements in biomarker development, including plasma and imaging tests, are also enabling earlier diagnosis and the potential for preventive treatments before the onset of clinical symptoms. Catch Dr. Sharon Cohen on this episode of Pharmacy Times!
About us
Founded in 1996, Toronto Memory Program is a multidisciplinary, community based, medical facility specializing in the diagnosis and treatment of Alzheimer’s disease and related disorders. We have one of the largest clinical trial programs for Alzheimer’s disease in the country. Our program serves the interests of patients and stakeholders locally, nationally and internationally. Our medical director, Dr. Sharon Cohen, is a Canadian-trained neurologist specializing in behaviour and cognition and an internationally recognized expert in this field.
- Website
-
http://www.torontomemoryprogram.com
External link for Toronto Memory Program
- Industry
- Research Services
- Company size
- 11-50 employees
- Headquarters
- Toronto, ON
- Type
- Privately Held
- Founded
- 1996
- Specialties
- Memory Clinic, Dementia, Alzheimer's disease, and Clinical Trials
Locations
-
Primary
1 Valleybrook Dr.
Suite 400
Toronto, ON M3C 1M9, CA
Employees at Toronto Memory Program
-
C. Ian Cohen
President -TMP Headlands Research ULC. Sport and Exercise Medicine Physician, David L. MacIntosh Sport Medicine Clinic, U of T
-
Eva Lizad dela Paz
--
-
Amelia Hansen
Adult/ Geriatric Nurse Practitioner
-
Atif Shaikh, CCRP
Clinical Research Coordinator at Toronto Memory Program
Updates
-
We are pleased to announce that Great Britain has become the first country in Europe to grant authorization for lecanemab (Leqembi), a treatment for mild cognitive impairment and mild dementia due to Alzheimer's disease. This is a significant step forward in the fight against Alzheimer's disease, as lecanemab is the first treatment in Europe to target an underlying cause of the disease by reducing amyloid-beta plaques.
Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain | Biogen
investors.biogen.com
-
Toronto Memory Program reposted this
FREE MEMORY TESTING 🧠 TNO is proud to collaborate with Toronto Memory Program, Canada’s largest Alzheimer’s disease clinic, to offer free memory testing for English-speaking adults aged 50-90. 📅 Dates: Sept 3rd & Sept 12th 📍 Location: Youth Hub, East York Town Centre, 45 Overlea Blvd (Entrance 6), Toronto, ON M4H 1C3 What you’ll get: Free memory testing Healthy aging resources Access to specialists at Toronto Memory Program BOOK YOUR APPOINTMENT TODAY! To register, contact: Elaine Tountas at 416-424-2900 Ext. 4704 or [email protected] #MemoryTesting #HealthyAging #TNO #Toronto #seniors #CommunitySupport #BrainHealth #SeniorCare #AgingWell #HealthScreening #TNOEvents
-
-
Meet Arshi Semy, our dedicated Diversity and Inclusion Officer at the Toronto Memory Program. Arshi plays a pivotal role in driving our commitment to diversity in Alzheimer's research. The banner and brochure she designed highlight her impactful work in ensuring our research represents all communities.
-
-
Toronto Memory Program reposted this
“I joined an Alzheimer’s clinical trial because I fervently believe that eventually Alzheimer’s Disease (AD) can be prevented. I feel extremely fortunate to be involved in a clinical research trial, partially because I’m not very good at ‘sitting still’. I feel that I am contributing to advancement of knowledge and progression of research to find a way to cure or prevent AD." #CitizenScientist Gwen from #GAPNet site Toronto Memory Program on why she chooses to volunteer to accelerate clinical research https://lnkd.in/gzXSjYUV
-
-
Toronto Memory Program reposted this
Awesome #DAC Featured Research Session this morning at #AAIC24. Last day, last session, and we still had great attendance and questions until the last possible minute! Namely because of our fantastic speakers and their fantastic results! #earlydetection #healthsystempreparedness Davos Alzheimer's Collaborative Alzheimer's Association® Barak Gaster Lori Frank Katie Selzler, PhD Michael Hornbecker Dr. Jane Mahakian Dan B. Christine Musyimi, Ph.D Brooks Kenny Amy Deckert, PhD Toronto Memory Program Tim MacLeod, PhD
-
-
A blood test with 90% accuracy can now detect early signs of Alzheimer's disease, far outperforming traditional methods. At Toronto Memory Program, these groundbreaking tests are offered through research participation, paving the way for early diagnosis and preventive care.
Alzheimer's blood test catches 90 per cent of early dementia cases, study finds — CTV News
apple.news
-
Toronto Memory Program reposted this
Is there a difference between Alzheimer’s disease and dementia? Gain a deeper understanding of Alzheimer's disease with the new audio miniseries from Health UNMUTED: “Rethinking Alzheimer’s Disease”. "Alzheimer's disease is characterized by a specific set of changes in the brain that can be identified and distinguished from other causes of dementia." - Dr. Sharon Cohen, Neurologist and Medical Director, Toronto Memory Program On the podcast, we talk to experts, caregivers and people living with Alzheimer’s to explore the complexities of Alzheimer's disease and provide support to people affected by it. Tune into Rethinking Alzheimer’s Disease, subscribe and share with the people in your life affected by this neurodegenerative disease. #Alzheimers #dementia #alzheimersawareness #caregiving #dementiaawareness #alzheimersdisease #HealthUNMUTED #AAIC24 https://lnkd.in/eJzFM2Kc Eisai US , Eisai U.S. Alzheimer’s Disease and Brain Health
-
Many factors may influence your risk of dementia, including genes, environment, and lifestyle. You can’t change some factors, but, as with many diseases, there may be steps you can take to help lower your risk. In general, leading a healthy lifestyle may help address risk factors that have been associated with Alzheimer’s disease and related dementias.
-